New Type 2 Diabetes Drug Kombiglyze XR Now Available Across the US
New Type 2 Diabetes Drug Kombiglyze XR Now Available Across the US
Shares
Bristol-Myers Squibb Company and AstraZeneca announced that type 2 diabetes drug Kombiglyze XR (saxagliptin and metformin HCl extended-release), approved by the FDA on November 5, 2010, is now available by prescription in pharmacies across the United States. Kombiglyze XR is the first and only once-a-day metformin extended-release (XR) plus dipeptidyl peptidase-4 (DPP-4) inhibitor combination tablet offering strong glycemic control across hemoglobin A1c levels, fasting plasma glucose and post-prandial glucose.Kombiglyze XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both saxagliptin and metformin is appropriate. Kombiglyze XR should not be used for patients with type 1 diabetes or diabetic ketoacidosis and has not been studied in combination with insulin.
Consistent with the Prescribing Information (PI) for metformin alone, the PI for Kombiglyze XR contains a boxed warning for lactic acidosis, a rare, but serious metabolic complication that can occur due to metformin accumulation during treatment with Kombiglyze XR.
Once-a-day Kombiglyze XR combines saxagliptin (also known as ONGLYZA™), a DPP-4 inhibitor, and metformin XR, a biguanide, in one tablet for the treatment of type 2 diabetes. Kombiglyze XR should generally be administered once a day with the evening meal, with gradual dose titration to reduce the gastrointestinal side effects associated with metformin. The maximum daily recommended dose is 5 mg for saxagliptin and 2,000 mg for metformin extended-release.
Now Available: Free Dexcom G6 Samples This week, Dexcom announced a new sampling program named “Hello Dexcom.” The program will allow healthcare professionals to order one-time samples of the Dexcom G6 to distribute to patients, free…
Running Across the USA with Type 1 Diabetes Don Muchow, Ironman and ultra-marathoner, deserves a special place in the annals of athletes with Type 1 diabetes. But what’s truly remarkable about Don’s story is that he spent the…
Chaffle Fever Sweeps Across the Globe Sometimes a food phenomenon comes ripping across the world, unbidden and unexpected, burning across social media like a wildfire, sweeping up innocents like a tidal wave. What is this force…
Did a Common Cholesterol Drug Reverse One Teen’s… Did fenofibrate – a common cholesterol drug – reverse one 19-year old woman’s newly diagnosed Type 1 diabetes? This is the question at the heart of a tantalizing medical mystery…
Type 2 Diabetes and COVID-19: What We Know Now Our early understanding of the novel coronavirus, and the CDC recommendations that have largely driven American policy and behavior, were based almost entirely on the first reports to trickle out…